CECILIA全球单臂II期研究主要结果:贝伐珠单抗联合卡铂和紫杉醇治疗晚期宫颈癌
CECILIA是一项全球单臂II期研究,评估贝伐珠单抗联合卡铂-紫杉醇治疗转移/复发/持续性宫颈癌。150例患者中,胃肠道穿孔/瘘发生率为4.7%,胃肠道-阴道瘘4.0%,泌尿生殖道瘘4.7%;客观缓解率61%,中位无进展生存期10.9个月,中位总生存期25.0个月。结论认为贝伐珠单抗可与卡铂-紫杉醇联合,瘘/穿孔发生率与GOG-0240一致,疗效结果令人鼓舞。
要点
- 贝伐珠单抗联合卡铂-紫杉醇方案中,≥1次穿孔/瘘事件发生率为11.3%(95% CI 6.7-17.5%)。
- 客观缓解率61%(95% CI 52-69%),中位无进展生存期10.9个月,中位总生存期25.0个月。
- 最常见3/4级不良事件为中性粒细胞减少25%、贫血19%、高血压14%;5例(3%)发生致命性不良事件。
核心结论
- 在CECILIA研究人群中,贝伐珠单抗可与卡铂-紫杉醇联合使用。
- 瘘/胃肠道穿孔发生率与GOG-0240一致;疗效结果令人鼓舞。
研究设计与样本
- 全球单臂II期研究,纳入转移性/复发性/持续性宫颈癌且不适合根治性手术和/或放疗的患者。
- 治疗方案为每3周一次贝伐珠单抗15 mg/kg、紫杉醇175 mg/m2、卡铂AUC 5,直至疾病进展或不可接受的毒性;允许贝伐珠单抗维持治疗。
- 排除标准包括持续膀胱/直肠受累、既往钴放疗、瘘/胃肠道穿孔史、近期肠切除/放化疗。
- 主要目标为确定胃肠道穿孔/瘘、胃肠道-阴道瘘和泌尿生殖道瘘的发生率。
- 共150例患者接受治疗;研究入组时疾病状态为持续性21%、复发性56%、新诊断转移性23%。
主要发现
- 中位随访27.8个月,贝伐珠单抗中位使用时长6.7个月;57%接受维持贝伐珠单抗。
- 17例(11.3%;95% CI 6.7-17.5%)发生≥1次穿孔/瘘事件:胃肠道穿孔/瘘4.7%(95% CI 1.9-9.4%),胃肠道-阴道瘘4.0%(95% CI 1.5-8.5%),泌尿生殖道瘘4.7%(95% CI 1.9-9.4%)。
- 上述17例中16例既往接受过放疗,部分存在持续放疗效应。
- 最常见3/4级不良事件:中性粒细胞减少25%、贫血19%、高血压14%;5例(3%)发生致命性不良事件。
- 客观缓解率61%(95% CI 52-69%),中位无进展生存期10.9(95% CI 10.1-13.7)个月,中位总生存期25.0(95% CI 20.9-30.4)个月。
关键数值与推荐
- 贝伐珠单抗15 mg/kg、紫杉醇175 mg/m2、卡铂AUC 5,每3周一次。
- 主要终点发生率:胃肠道穿孔/瘘4.7%(95% CI 1.9-9.4%),胃肠道-阴道瘘4.0%(95% CI 1.5-8.5%),泌尿生殖道瘘4.7%(95% CI 1.9-9.4%)。
- 客观缓解率61%(95% CI 52-69%),中位无进展生存期10.9(95% CI 10.1-13.7)个月,中位总生存期25.0(95% CI 20.9-30.4)个月。
临床怎么用
- 作者认为在CECILIA研究人群中贝伐珠单抗可与卡铂-紫杉醇联合使用,瘘/胃肠道穿孔发生率与GOG-0240一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Adding bevacizumab to cisplatin-paclitaxel for advanced cervical cancer significantly improves overall and progression-free survival. We evaluated bevacizumab with a widely used carboplatin-paclitaxel backbone. METHODS: Patients with metastatic/recurrent/persistent cervical cancer not amenable to curative surgery and/or radiotherapy received 3-weekly bevacizumab 15 mg/kg, paclitaxel 175 mg/m2, and carboplatin AUC 5 until progression or unacceptable toxicity. Maintenance bevacizumab was allowed. Patients with ongoing bladder/rectal involvement, prior cobalt radiotherapy, a history of fistula/gastrointestinal perforation, or recent bowel resection/chemoradiation were excluded. The primary objective was to determine incidences of gastrointestinal perforation/fistula, gastrointestinal-vaginal fistula, and genitourinary fistula. RESULTS: Among 150 treated patients, disease at study entry was persistent in 21%, recurrent in 56%, and newly diagnosed metastatic in 23%. After 27.8 months' median follow-up, median bevacizumab duration was 6.7 months; 57% received maintenance bevacizumab. Seventeen patients (11.3%; 95% CI: 6.7-17.5%) experienced ≥1 perforation/fistula event: gastrointestinal perforation/fistula in 4.7% (1.9-9.4%), gastrointestinal-vaginal fistula in 4.0% (1.5-8.5%), and genitourinary fistula in 4.7% (1.9-9.4%). Of these, 16 were previously irradiated, several with ongoing radiation effects. The most common grade 3/4 adverse events were neutropenia (25%), anemia (19%), and hypertension (14%). Five patients (3%) had fatal adverse events. Objective response rate was 61% (95% CI: 52-69%), median progression-free survival was 10.9 (10.1-13.7) months, and median overall survival was 25.0 (20.9-30.4) months. CONCLUSIONS: Bevacizumab can be combined with carboplatin-paclitaxel in the CECILIA study population. The fistula/gastrointestinal perforation incidence is in line with GOG-0240; efficacy results are encouraging. TRIAL REGISTRATION NUMBER: NCT02467907 (ClinicalTrials.gov).
引用
- Redondo A, Colombo N, McCormack M, et al. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. Gynecol Oncol. 2020. PMID: 32763109. doi:10.1016/j.ygyno.2020.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。